Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories : vimarsana.com

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories

finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Related Keywords

Lesen , Aquitaine , France , Castres , Midi Pyrées , China , Delaware , United States , Wilson Sonsini Goodrich Rosati , Pierre Fabre , Laurence Marchal , Nima Farzan , Francesco Hofmann , Pierre Fabre Laboratorie , Prnewswire Kinnate Biopharma Inc , Lazard , Kinnate Biopharma Inc , Development For Medical Care , Head Of Research , Exchange Commission , Approval Program , Nasdaq , Linkedin , Pierre Fabre Laboratorie Head Of Research , Asset Purchase Agreement , Pierre Fabre Laboratories , Chief Executive Officer , Medical Care , Contingent Value Rights Agreement , Wilson Sonsini Goodrich , Additional Information , Recommendation Statement , Common Stock , Pierre Fabre Laboratorie Head , Merger Agreement , Merger Sub , Fabre Laboratories Media Contact ,